MAVENCLAD™ (cladribine tablets) │ EMD Serono
We're sorry, but we're unable to process your login. Please try again.
We're sorry, you are not authorized to access this site. Please contact your local Merck KGaA, Darmstadt, Germany representative.
This page requires you to register for an account with Merck KGaA, Darmstadt, Germany.
Sign-in
{* #signInForm *}
{* signInEmailAddress *}
{* currentPassword *}
{* captcha *}
{* /signInForm *}

Dosing and administration

MAVENCLAD™ HAS A WEIGHT-BASED DOSING REGIMEN1

MAVENCLAD is administered as one treatment course per year over 2 years, followed by observation for another 2 years. Each treatment course consists of 2 treatment weeks: week 1 and week 5.1

Dosing Guide Dosing Guide

This dosing tool will display the correct MAVENCLAD dose by patient weight per treatment year.

Please enter your patient's weight:
Please only enter numbers up to one decimal place

WEEK 1
pill pill
WEEK 5
Day 1 0 0 Day 1
Day 2 0 0 Day 2
Day 3 0 0 Day 3
Day 4 0 0 Day 4
Day 5 0 0 Day 5
Total Tablets
0
0
0
0
0
0

Use of MAVENCLAD in patients weighing less than 40 kg has not been investigated. Please enter a value ≥40 kg.

Full Dosing Table

Dosing Table Dosing Table

Learn more about MAVENCLAD

 

Demonstrated efficacy

Monitoring

Safety and tolerability profile

  

 

Explore MAVENCLAD’s efficacy.

Learn more

Discover MAVENCLAD’s monitoring.

Learn more

Learn about MAVENCLAD’s safety and
tolerability profile.

Learn more

  
Footnotes and References
  1. MAVENCLAD™ Product Monograph. EMD Serono. November 2017.
  2. Giovannoni G, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010;362:416-26.
Cookie Disclaimer

This website uses 'cookies' to give you the best, most relevant experience. Using this website means you’re OK with this. You can change which cookies are set at any time - and find out more about them in our Cookie policy.

OK, GOT IT

You are leaving our website

You are now leaving our website. This link may lead to a resource maintained by third parties over whom we have no control. As such, we are not responsible for and make no representation to the accuracy or any other aspect of such resource or the privacy practices of such third party. Providing links to a third-party website does not constitute an endorsement by our company of such website or the information or products presented on such website.

lightbox image